Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Brodsky, R. A.    Jones, R. J.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia

Robert A. Brodsky, MD; Lyle L. Sensenbrenner, MD; B. Douglas Smith, MD; Donna Dorr, RN; Phillip J. Seaman, PA-C; Shing M. Lee, ScM; Judith E. Karp, MD; Isadore Brodsky, MD; and Richard J. Jones, MD

2 October 2001 | Volume 135 Issue 7 | Pages 477-483

Background: Severe aplastic anemia is a life-threatening bone marrow failure disorder. High-dose cyclophosphamide therapy followed by allogeneic bone marrow transplantation cures the disease. However, it requires a suitable donor and carries the risk for graft-versus-host disease. A small pilot study demonstrated that high-dose cyclophosphamide therapy without bone marrow transplantation leads to durable, treatment-free complete remission.

Objective: To confirm the safety and efficacy of high-dose cyclophosphamide therapy alone in patients with severe aplastic anemia.

Design: Uncontrolled clinical trial.

Setting: Three tertiary care hospitals.

Patients: 19 patients with untreated severe aplastic anemia.

Intervention: Cyclophosphamide, 50 mg/kg of body weight per day for 4 consecutive days.

Measurements: Probability of response and overall survival were measured. Complete remission was defined as normal blood count for age and sex. Partial remission was defined as independence from transfusion and an absolute neutrophil count greater than 0.5 x 10⁹ cells/L without growth factor support. Nonresponders were patients who remained transfusion dependent or died. Relapse was defined as no longer meeting criteria for partial or complete remission.

Results: The median time to an absolute neutrophil count of 0.5 x 10⁹ cells/L was 49 days. The probability of survival was 84% (95% CI, 59% to 95%) at 24 months. The probability of achieving treatment-free remission was 73% (CI, 51% to 91%) at 24 months, and the probability of achieving complete remission was 65% (CI, 39% to 89%) at 50 months. No responding patients have had relapse or have developed secondary clonal disorders.

Conclusions: High-dose cyclophosphamide therapy without bone marrow transplantation produces durable treatment-free remission in severe aplastic anemia. This approach deserves further study in patients with severe aplastic anemia who are not suitable candidates for allogeneic bone marrow transplantation.

Author and Article Information

From the Johns Hopkins Oncology Center and the Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland; and MCP Hahnemann University, Philadelphia, Pennsylvania.

Acknowledgment: The authors thank the physicians, nurses, and support staff of the Johns Hopkins University Bone Marrow Transplant Team, MCP Hahnemann University, and the Greenbaum Cancer Center for their excellent patient care.

Grant Support: In part by grant CA70970 from the National Institutes of Health. Dr. R. Brodsky is a Leukemia and Lymphoma Society Clinical Research Scholar and The Thomas E. Sandefur Jr. Fellow in Stem Cell Research.

Request for Single Reprints: Robert A. Brodsky, MD, Johns Hopkins Oncology Center, Bunting-Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore, MD 21231; e-mail, rbrodsky{at}jhmi.edu.

Current Author Addresses: Dr. R. Brodsky, Dr. Smith, Ms. Dorr, Mr. Seaman, and Dr. Jones: Johns Hopkins Oncology Center, Bunting-Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore MD 21231.

Dr. Sensenbrenner: 1613 Camden Avenue, Salisbury, MD 21801-7010.

Ms. Lee: Johns Hopkins Oncology Center, Oncology Biostatistics, 550 North Broadway, Suite 1103, Baltimore, MD 21205.

Dr. I. Brodsky: MCP Hahnemann University, Broad and Vine Streets, Mailstop 412, Philadelphia, PA 19102.

Dr. Karp: Greenbaum Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room S9D15, Baltimore, MD 21201-1544.

Author Contributions: Conception and design: R.A. Brodsky, L.L. Sensenbrenner, R.J. Jones.

Analysis and interpretation of the data: R.A. Brodsky, B.D. Smith, J.E. Karp, I. Brodsky, R.J. Jones.

Drafting of the article: R.A. Brodsky.

Critical revision of the article for important intellectual content: L.L. Sensenbrenner, B.D. Smith, R.J. Jones.

Final approval of the article: R.A. Brodsky, R.J. Jones.

Provision of study materials or patients: R.A. Brodsky, J.E. Karp, I. Brodsky.

Statistical expertise: S.M. Lee.

Obtaining of funding: R.A. Brodsky, R.J. Jones.

Administrative, technical, or logistic support: B.D. Smith, D. Dorr, P.J. Seaman.

Collection and assembly of data: R.A. Brodsky, B.D. Smith, D. Dorr, P.J. Seaman.

Related articles in Annals:

Editorials
Aplastic Anemia: Which Treatment?
Janis L. Abkowitz

Annals 2001 135: 524-526. [Full Text]  

Summaries for Patients
High-Dose Cyclophosphamide To Treat Severe Aplastic Anemia

Annals 2001 135: S42. [Full Text]  

Letters
High-Dose Cyclophosphamide for Treatment of Aplastic Anemia
Neal S. Young AND John F. Tisdale

Annals 2002 137: 549-550. [Full Text]  

Letters
High-Dose Cyclophosphamide for Treatment of Aplastic Anemia
Robert A. Brodsky AND Richard J. Jones

Annals 2002 137: 550. [Full Text]  

This article has been cited by other articles:

				C V Tehlirian, L K Hummers, B White, R A Brodsky, and F M Wigley High-dose cyclophosphamide without stem cell rescue in scleroderma Ann Rheum Dis, June 1, 2008; 67(6): 775 - 781. [Abstract] [Full Text] [PDF]

				N. S. Young, R. T. Calado, and P. Scheinberg Current concepts in the pathophysiology and treatment of aplastic anemia Blood, October 15, 2006; 108(8): 2509 - 2519. [Abstract] [Full Text] [PDF]

				D. E. Gladstone, K. W. Zamkoff, L. Krupp, R. Peyster, P. Sibony, C. Christodoulou, E. Locher, and P. K. Coyle High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis Arch Neurol, October 1, 2006; 63(10): 1388 - 1393. [Abstract] [Full Text] [PDF]

				R. A. Brodsky New Insights into Paroxysmal Nocturnal Hemoglobinuria Hematology, January 1, 2006; 2006(1): 24 - 28. [Abstract] [Full Text] [PDF]

				T Daikeler, C Erley, M Mohren, C Amberger, H Einsele, L Kanz, and I Kotter Fever and increasing cANCA titre after kidney and autologous stem cell transplantation for Wegener's granulomatosis Ann Rheum Dis, April 1, 2005; 64(4): 646 - 647. [Full Text] [PDF]

				E. C. Guinan Aplastic Anemia: Management of Pediatric Patients Hematology, January 1, 2005; 2005(1): 104 - 109. [Abstract] [Full Text] [PDF]

				J. P. Maciejewski and A. M. Risitano Aplastic Anemia: Management of Adult Patients Hematology, January 1, 2005; 2005(1): 110 - 117. [Abstract] [Full Text] [PDF]

				G. C. Bagby, J. M. Lipton, E. M. Sloand, and C. A. Schiffer Marrow Failure Hematology, January 1, 2004; 2004(1): 318 - 336. [Abstract] [Full Text] [PDF]

				S. Rosenfeld, D. Follmann, O. Nunez, and N. S. Young Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia: Association Between Hematologic Response and Long-term Outcome JAMA, March 5, 2003; 289(9): 1130 - 1135. [Abstract] [Full Text] [PDF]

				J. F. Tisdale, J. P. Maciejewski, O. Nunez, S. J. Rosenfeld, and N. S. Young Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial Blood, December 15, 2002; 100(13): 4668 - 4670. [Abstract] [Full Text] [PDF]

				N. S. Young and J. F. Tisdale High-Dose Cyclophosphamide for Treatment of Aplastic Anemia Ann Intern Med, September 17, 2002; 137(6): 549 - 550. [Full Text] [PDF]

				D D'Cruz High-dose intravenous cyclophosphamide therapy in severe SLE Lupus, July 1, 2002; 11(7): 403 - 404. [PDF]

				D E Gladstone, A A Prestrud, A Pradhan, M J Styler, D L Topolsky, P A Crilley, S Hoch, A Huppert, and I Brodsky High-dose cyclophosphamide for severe systemic lupus erythematosus Lupus, July 1, 2002; 11(7): 405 - 410. [Abstract] [PDF]

				V. M. Moyo, D. Smith, I. Brodsky, P. Crilley, R. J. Jones, and R. A. Brodsky High-dose cyclophosphamide for refractory autoimmune hemolytic anemia Blood, June 28, 2002; 100(2): 704 - 706. [Abstract] [Full Text] [PDF]

				T.H. Brannagan III, A. Pradhan, T. Heiman-Patterson, A.C. Winkelman, M.J. Styler, D.L. Topolsky, P.A. Crilley, R.J. Schwartzman, I. Brodsky, and D.E. Gladstone High-dose cyclophosphamide without stem-cell rescue for refractory CIDP Neurology, June 25, 2002; 58(12): 1856 - 1858. [Abstract] [Full Text] [PDF]

				N. S. Young Acquired Aplastic Anemia Ann Intern Med, April 2, 2002; 136(7): 534 - 546. [Abstract] [Full Text] [PDF]

				Promising Treatment for Aplastic Anemia Journal Watch (General), October 12, 2001; 2001(1012): 1 - 1. [Full Text]

				J. L. Abkowitz Aplastic Anemia: Which Treatment? Ann Intern Med, October 2, 2001; 135(7): 524 - 526. [Full Text] [PDF]